detti F.

Nierenberg AA, Katz J, Fava M. A critical overview of the pharmacologic

et al. Acute and longer-term outcomes in depressed outpatients requiring
one or several treatment steps: A STAR*D report. *Am J Psychiatry* 2006; 163:
1905–17.

Nierenberg AA, Katz J, Fava M. A critical overview of the pharmacologic
30: 13–29.

Evaluation of outcomes with citalopram for depression using measurement-
based care in STAR*D: implications for clinical practice. *Am J Psychiatry*

Benedetti F. *Placebo Effects: Understanding the Mechanism in Health and

Australian and New Zealand College of Psychiatrists clinical practice
guidelines for management of mood disorders. *Aus NZ J Psychiatry*, 2015:

Schoevers RA, Chaves TV, Balakova SM, aan het Rot M, Kortekaas R.
Oral ketamine for the treatment of pain and treatment-resistant depression.

Nguyen L, Marshalek PJ, Weaver CB, Cramer KJ, Scott EP, Matsumoto RR.
Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a

DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Jofre FS, Dostrovsky JO.
The promise of ketamine for treatment-resistant depression: current evidence

McGirt A, Bellem MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic
review of meta-analysis of randomized, double-blind, placebo-controlled
trials of ketamine in the rapid treatment of major depressive episodes.

Kirby T. Ketamine for depression: the highs and lows. *Lancet Psychiatry*

Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB.
Ketamine and other NMDA antagonists: early clinical trials and possible

Rasmussen KG. Has psychiatry tamed the ‘ketamine tiger’? Considerations
on its use for depression and anxiety. *Neuro-Psychopharmacol Biol

Rapid and longer-term antidepressant effects of repeated ketamine infusion

Neurocognitive effects of ketamine and association with antidepressant
response in individuals with treatment-resistant depression: a randomized

---

**References**

1 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D,
et al. Acute and longer-term outcomes in depressed outpatients requiring
one or several treatment steps: A STAR*D report. *Am J Psychiatry* 2006; 163:
1905–17.

2 Nierenberg AA, Katz J, Fava M. A critical overview of the pharmacologic
30: 13–29.

Evaluation of outcomes with citalopram for depression using measurement-
based care in STAR*D: implications for clinical practice. *Am J Psychiatry*

4 Benedetti F. *Placebo Effects: Understanding the Mechanism in Health and

Australian and New Zealand College of Psychiatrists clinical practice
guidelines for management of mood disorders. *Aus NZ J Psychiatry*, 2015:

6 Schoevers RA, Chaves TV, Balakova SM, aan het Rot M, Kortekaas R.
Oral ketamine for the treatment of pain and treatment-resistant depression.

7 Nguyen L, Marshalek PJ, Weaver CB, Cramer KJ, Scott EP, Matsumoto RR.
Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a

8 DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Jofre FS, Dostrovsky JO.
The promise of ketamine for treatment-resistant depression: current evidence

9 McGirt A, Bellem MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic
review of meta-analysis of randomized, double-blind, placebo-controlled
trials of ketamine in the rapid treatment of major depressive episodes.

10 Kirby T. Ketamine for depression: the highs and lows. *Lancet Psychiatry*

11 Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB.
Ketamine and other NMDA antagonists: early clinical trials and possible

12 Rasmussen KG. Has psychiatry tamed the ‘ketamine tiger’? Considerations
on its use for depression and anxiety. *Neuro-Psychopharmacol Biol

Rapid and longer-term antidepressant effects of repeated ketamine infusion

Neurocognitive effects of ketamine and association with antidepressant
response in individuals with treatment-resistant depression: a randomized

---

**A hospital for the mentally ill in the Middle Ages**

**Fernando Espí Forcén**

The Hospital de Folls de Santa María dels Pobres Innocents (Hospital for the Mad of
Saint Mary of the Poor Innocents) was founded by Father Joan Gilabert Jofre in May
1409 and opened in June 1410 with the financial support of Lorenzo Saloni and the
approval of King Martin I of Aragon and Pope Benedictus XIII. At that time,
‘innocents’ was a term used to describe children, people with intellectual disability
and people with severe mental illness.

The hospital was conceived as a safe place for people with mental illness. Months
before its foundation, Father Jofre had publicly preached against the irrational
persecution of the mentally ill and in favour of creation of a special hospital, having
seen how both mentally ill men and women were physically and sexually abused
and left freezing and starving in the streets. Through the centuries the hospital
advocated for the mentally ill and became a pioneer in occupational therapy:
men carried out activities in agriculture and women in sewing and knitting. The
hospital also became a shelter for orphaned children who lived in the streets. After severe damage by fire in 1547 the building
was reconstructed and went through several restorations over the centuries. Since 1963 it has housed the Valencia Public Library.

The gate of the hospital’s main entrance from the original 1409 structure has surprisingly survived through the centuries. In the
image we can see a characteristic Gothic framed pointed arch with two responds on the sides congruent with the characteristic
architectural style in Valencia during the early 15th century. The former tympanum contains today a sculpture of Saint Mary of
the Innocents holding baby Jesus.

It is believed that Father Jofre found inspiration in the way mentally ill people received care at the Maristan of Sidi Frej in Fez,
Morocco, as he had taken several trips to Muslim territories and was probably exposed to the way mentally ill people received
care in the Islamic world. Following the opening of the hospital in Valencia, a similar hospital was founded a few years later in
Saragossa, Spain. It was praised by Philippe Pinel at the time of the foundation of moral treatment.

At a time in which a religious approach was often taken to explain mental illness, the Hospital of Valencia is proof of early
advocacy and treatment for the mentally ill in the Middle Ages.

Published with the kind permission of Carlos Espí Forcén.
A hospital for the mentally ill in the Middle Ages – psychiatry in history
Fernando Espí Forcén
BJP 2016, 208:103.
Access the most recent version at DOI: 10.1192/bjp.bp.115.166108

References
This article cites 0 articles, 0 of which you can access for free at:
http://bjp.rcpsych.org/content/208/2/103#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;208/2/103

Downloaded from
http://bjp.rcpsych.org/ on October 14, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/